Bristol-Myers Squibb $BMY
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS89
PHASE 3 / 2-358
RECRUITING48
READOUTS ≤12 MONTHS13
READOUT SLIPPED >6 MO34%
Delay Index: of 73 active trials registered more than a year ago, 25 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Bristol-Myers Squibb on the live radar map → 📅 $BMY readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| RELATIVITY-047 NCT03470922 |
P2/3 | Active, not recruiting | Melanoma | 714 | 2021-01-25 (+6 mo) |
| CheckMate76K NCT04099251 |
P3 | Active, not recruiting | Melanoma | 790 | 2022-06-28 (-18 mo) |
| Abatacept NCT04909801 |
P3 | Active, not recruiting | Rheumatoid Arthritis | 338 | 2023-06-14 (-23 mo) |
| Nivolumab NCT04025879 |
P3 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | 461 | 2023-07-26 (+2 mo) |
| Deucravacitinib NCT04857034 |
P2 | Active, not recruiting | Lupus Erythematosus, Discoid; Lupus Erythematosus, Subacute Cutaneous | 74 | 2024-08-22 (+2 mo) |
| CheckMate 8HW NCT04008030 |
P3 | Active, not recruiting | Metastatic Colorectal Cancer | 839 | 2024-08-28 (-2 mo) |
| Deucravacitinib NCT04908202 |
P3 | Active, not recruiting | Psoriatic Arthritis | 670 | 2024-10-10 (+12 mo) |
| Deucravacitinib NCT04908189 |
P3 | Active, not recruiting | Psoriatic Arthritis | 729 | 2024-11-07 (+13 mo) |
| Oral Azacitidine NCT05197426 |
P2 | Active, not recruiting | Acute Myeloid Leukemia | 19 | 2025-01-27 (+7 mo) |
| relatlimab+nivolumab NCT06101134 |
P2 | Active, not recruiting | Melanoma | 100 | 2025-04-10 (-5 mo) |
| CheckMate-67T NCT04810078 |
P3 | Active, not recruiting | Clear Cell Renal Cell Carcinoma | 681 | 2025-07-29 (+20 mo) |
| Luspatercept NCT05567458 |
P2 | Active, not recruiting | Beta-thalassemia | 94 | 2025-08-01 (+6 mo) |
| RELATIVITY-127 NCT05625399 |
P3 | Active, not recruiting | Melanoma | 579 | 2025-08-04 (+5 mo) |
| MAXILUS NCT06045689 |
P3 | Active, not recruiting | Myelodysplastic Syndromes | 106 | 2025-10-01 (-3 mo) |
| CC-486 NCT05413018 |
P2 | Active, not recruiting | Leukemia, Myeloid, Acute | 34 | 2025-10-31 (+11 mo) |
| Mavacamten NCT06253221 |
P3 | Active, not recruiting | Cardiomyopathy, Hypertrophic | 44 | 2025-11-25 (-27 mo) |
| CheckMate 9DX NCT03383458 |
P3 | Active, not recruiting | Hepatocellular Carcinoma; Liver Cancer | 545 | 2026-05-27 (+51 mo) |
| BMS-986369 NCT06035497 |
P1/2 | Active, not recruiting | Relapsed or Refractory T-cell Lymphomas | 83 | 2026-08-11 (-5 mo) |
| BMS-986490 NCT06730750 |
P1/2 | Active, not recruiting | Advanced Solid Tumors | 360 | 2026-09-05 |
| SUCCESSOR-2 NCT05552976 |
P3 | Active, not recruiting | Relapsed or Refractory Multiple Myeloma | 606 | 2026-09-28 (+8 mo) |
| BMS-986449 NCT05888831 |
P1/2 | Active, not recruiting | Advanced Solid Tumors | 100 | 2026-09-30 (+16 mo) |
| BMS-986278 NCT06003426 |
P3 | Active, not recruiting | Idiopathic Pulmonary Fibrosis | 1255 | 2026-10-06 |
| CC-92480 NCT05372354 |
P1/2 | Recruiting | Multiple Myeloma | 260 | 2026-10-12 (+18 mo) |
| POETYK SLE-1 NCT05617677 |
P3 | Active, not recruiting | Systemic Lupus Erythematosus | 516 | 2026-10-19 (+10 mo) |
| POETYK SLE-2 NCT05620407 |
P3 | Active, not recruiting | Systemic Lupus Erythematosus | 513 | 2026-10-19 (+10 mo) |
| BALSAM-1 NCT06951698 |
P3 | Recruiting | Bipolar-I Disorder With Mania or Mania With Mixed Features | 274 | 2026-11-01 |
| KarXT NCT06951711 |
P3 | Recruiting | Bipolar Disorder Type I With Mania or Mania With Mixed Features | 274 | 2026-11-02 |
| POETYK SjS-1 NCT05946941 |
P3 | Active, not recruiting | Sjögren's Syndrome | 774 | 2026-11-18 |
| AURORA-HFpEF NCT06122779 |
P2 | Active, not recruiting | Heart Failure | 227 | 2026-12-14 (+23 mo) |
| TargetTau-1 NCT06268886 |
P2 | Active, not recruiting | Alzheimer Disease, Early Onset | 310 | 2026-12-17 (-3 mo) |
| BMS-986470 NCT06481306 |
P1/2 | Recruiting | Anemia, Sickle Cell; Healthy Volunteers | 224 | 2027-01-06 |
| CheckMate-1533 NCT06946797 |
P2 | Active, not recruiting | Non-Small Cell Lung Cancer | 76 | 2027-02-05 |
| Repotrectinib NCT06140836 |
P3 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | 190 | 2027-02-16 (-24 mo) |
| Nivolumab NCT03873402 |
P3 | Active, not recruiting | Renal Cell Carcinoma | 437 | 2027-03-11 (+50 mo) |
| Xanomeline/Trospium Chloride NCT07140913 |
P3 | Recruiting | Mania; Bipolar Disorder | 424 | 2027-06-28 |
| Luspatercept NCT05664737 |
P2 | Active, not recruiting | Anemia | 189 | 2027-07-16 (+20 mo) |
| BMS-986489 (Atigotatug+Nivolumab) NCT06646276 |
P3 | Recruiting | Extensive-Stage Small Cell Lung Cancer | 530 | 2027-08-17 (-8 mo) |
| BMS-986458 NCT06090539 |
P1/2 | Recruiting | Relapsed/Refractory Non-Hodgkin Lymphoma | 460 | 2027-10-28 |
| BMS-986278 NCT06025578 |
P3 | Active, not recruiting | Progressive Pulmonary Fibrosis | 1057 | 2027-12-27 |
| KarXT NCT06947941 |
P3 | Recruiting | Alzheimer Disease; Psychosis | 325 | 2028-02-21 (+5 mo) |
| Iza-bren NCT06926868 |
P2/3 | Recruiting | Breast Neoplasms | 600 | 2028-03-13 |
| Pumitamig NCT07871214 |
P2 | Not yet recruiting | Early-Stage Non-Small Cell Lung Cancer | 80 | 2028-03-15 |
| ELEMENT-MDS NCT05949684 |
P3 | Active, not recruiting | Myelodysplastic Syndromes | 402 | 2028-03-24 (+9 mo) |
| KarXT NCT06929273 |
P3 | Recruiting | Bipolar Disorder Type I With Mania | 450 | 2028-06-13 |
| Oral Azacitidine NCT05469737 |
P2/3 | Active, not recruiting | Myelodysplastic Syndromes | 230 | 2028-07-31 (+31 mo) |
| BMS-986517 NCT07160725 |
P1/2 | Recruiting | Solid Tumours | 540 | 2028-07-31 |
| Navlimetostat NCT07492680 |
P2 | Recruiting | Solid Tumors | 254 | 2028-08-15 |
| BMS-986158 NCT04817007 |
P1/2 | Active, not recruiting | Myelofibrosis | 216 | 2028-08-31 (+58 mo) |
| MINDSET 1 NCT06976216 |
P3 | Recruiting | Alzheimer's Disease | 586 | 2028-09-11 |
| MINDSET 2 NCT06976203 |
P3 | Recruiting | Alzheimer's Disease | 586 | 2028-09-11 |
| Pumitamig NCT07680764 |
P2 | Recruiting | Locally Advanced Non-Small Cell Lung Cancer (NSCLC); Metastatic Non-Small Cell Lung Cancer (NSCLC) | 160 | 2028-09-15 |
| KarXT NCT06882785 |
P3 | Recruiting | Schizophrenia | 250 | 2028-09-23 |
| BMS-986523 NCT07223047 |
P1/2 | Recruiting | Advanced Solid Malignancies; Non-small Cell Lung Cancer (NSCLC) | 252 | 2028-10-13 |
| Xanomeline/Trospium Chloride Capsule NCT07011745 |
P3 | Recruiting | Alzheimer's Disease | 426 | 2028-11-03 |
| BMS-986511 NCT07772531 |
P2 | Not yet recruiting | Major Depressive Disorder | 200 | 2028-11-06 |
| Xanomeline/Trospium Chloride Capsule NCT07011732 |
P3 | Recruiting | Alzheimer Disease | 426 | 2028-11-24 |
| Iza-bren NCT07100080 |
P2/3 | Recruiting | Non-Small Cell Lung Cancer | 661 | 2028-12-15 (+3 mo) |
| BMS-986504 NCT06855771 |
P2 | Recruiting | Carcinoma, Non-Small-Cell Lung | 182 | 2028-12-29 |
| Deucravacitinib NCT04772079 |
P3 | Recruiting | Plaque Psoriasis | 153 | 2029-01-01 (+57 mo) |
| BMS-986482 NCT06697197 |
P1/2 | Recruiting | Advanced Solid Tumors | 286 | 2029-01-04 |
| Iza-bren NCT07106762 |
P2/3 | Recruiting | Urothelial Cancer | 470 | 2029-01-26 |
| Iberdomide NCT05827016 |
P3 | Active, not recruiting | Multiple Myeloma | 1230 | 2029-03-15 |
| BMS-986525 NCT07325136 |
P1/2 | Recruiting | Relapsed/Refractory Small Cell Lung Cancer | 240 | 2029-04-23 |
| Navlimetostat NCT07076121 |
P2/3 | Active, not recruiting | Pancreatic Ductal Adenocarcinoma | 470 | 2029-05-03 |
| KarXT NCT06937229 |
P3 | Recruiting | Alzheimer Disease; Agitation | 650 | 2029-06-22 (+7 mo) |
| KarXT NCT07284745 |
P3 | Recruiting | Irritability Associated With Autism Spectrum Disorder | 176 | 2029-08-06 |
| KarXT NCT07285798 |
P3 | Recruiting | Irritability Associated With Autism Spectrum Disorder | 176 | 2029-08-06 |
| Nivolumab NCT03899155 |
P2 | Recruiting | Cancer | 1500 | 2029-08-25 (+111 mo) |
| POETYK-PsO-Ped NCT06979453 |
P3 | Recruiting | Plaque Psoriasis | 366 | 2029-10-12 |
| Pumitamig NCT07291076 |
P1/2 | Recruiting | Hepatocellular Carcinoma (HCC) | 198 | 2029-10-15 |
| BMS-986528 NCT07412704 |
P1/2 | Recruiting | Arthritis, Rheumatoid | 84 | 2029-10-30 |
| BMS-986278 NCT07441408 |
P3 | Not yet recruiting | Pulmonary Fibrosis | 2380 | 2029-11-22 |
| Pumitamig NCT07293351 |
P1/2 | Recruiting | Advanced Renal Cell Carcinoma (RCC) | 474 | 2029-11-28 |
| KarXT NCT07288567 |
P3 | Recruiting | Schizophrenia | 166 | 2029-12-18 |
| Pumitamig NCT07221357 |
P2/3 | Recruiting | Untreated, Unresectable, or Metastatic Colorectal Cancer | 990 | 2030-02-02 |
| Deucravacitinib NCT06869551 |
P3 | Recruiting | Juvenile Psoriatic Arthritis | 60 | 2030-03-06 |
| RELATIVITY1093 NCT06561386 |
P3 | Recruiting | Non-small Cell Lung Cancer | 1000 | 2030-07-30 |
| Pumitamig NCT07361497 |
P3 | Recruiting | Non-small Cell Lung Cancer (NSCLC) | 850 | 2030-09-18 |
| Deucravacitinib NCT07791199 |
P3 | Not yet recruiting | Systemic Lupus Erythematosus; Sjögren's Disease | 2300 | 2030-10-31 |
| Pumitamig NCT07221149 |
P2/3 | Recruiting | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | 690 | 2030-11-08 |
| Deucravacitinib NCT07116967 |
P3 | Recruiting | Plaque Psoriasis | 3040 | 2031-01-16 |
| BMS-986507 NCT06618287 |
P1/2 | Recruiting | Lung Cancer; Breast Cancer | 416 | 2031-02-26 (+51 mo) |
| Ozanimod NCT06408259 |
P3 | Recruiting | Multiple Sclerosis, Relapsing-Remitting | 194 | 2031-04-11 |
| MountainTAP-29 NCT07063745 |
P2/3 | Recruiting | Metastatic Non-small Cell Lung Cancer With MTAP Deletion | 590 | 2031-08-12 |
| BMS-986340 NCT04895709 |
P1/2 | Recruiting | Cervical Cancer; Gastric/Gastroesophageal Junction Adenocarcinoma | 1109 | 2031-08-31 (+89 mo) |
| Pumitamig NCT07361510 |
P3 | Recruiting | Non-Small Cell Lung Cancer (NSCLC) | 750 | 2031-10-14 |
| Iza-bren NCT07680790 |
P3 | Recruiting | Non-Small Cell Lung Cancer | 850 | 2031-12-30 |
| Ozanimod NCT05076175 |
P2/3 | Recruiting | Colitis, Ulcerative | 120 | 2032-07-12 (+81 mo) |
| Belatacept NCT04877288 |
P3 | Recruiting | Renal Allograft Recipients | 102 | 2032-12-30 (+77 mo) |